Premium
Fenofibrate‐Induced Elevation in Serum Creatinine
Author(s) -
Ritter Janet L.,
Nabulsi Shereen
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.13.1145.34623
Subject(s) - fenofibrate , creatinine , medicine , renal function , hyperlipidemia , drug , urology , gastroenterology , endocrinology , pharmacology , diabetes mellitus
Fenofibrate, a fibric acid derivative, is used as adjunctive therapy with diet for treatment of hyperlipidemia. Side effects include gastrointestinal complaints and, rarely, elevations in liver function tests. According to the drug's package insert, elevations in serum creatinine may occur; although, no postmarketing case reports of fenofibrate‐induced elevations in serum creatinine are on file with the manufacturer. Fenofibrate was the probable cause of elevations in serum creatinine concentrations in six patients at our clinic. As the implications of these elevations may be serious, routine serum creatinine monitoring is recommended at baseline and 1–2 months after starting fenofibrate.